About the SPORE
The goal of the University of Iowa/Mayo Clinic Lymphoma SPORE is to conduct innovative, interactive, translational research in lymphoma and chronic lymphocytic leukemia that accelerates progress in lymphoma research.
The Lymphoma SPORE takes advantage of the combined strengths of the translational lymphoma programs of the Holden Comprehensive Cancer Center at the University of Iowa and the Mayo Clinic Cancer Center — two National Cancer Institute-designated comprehensive cancer centers. At Mayo Clinic, the Lymphoma SPORE is part of the Hematologic Malignancies Program, a formal research program within the Mayo Clinic Cancer Center.
Despite progress in lymphoid malignancies, most types of lymphoma are still incurable.
In recent years, the Lymphoma SPORE has had numerous research advances to help find better treatments for lymphoma and chronic lymphocytic leukemia. The Lymphoma SPORE identified new tumor markers and made discoveries that led to additional translational lymphoma grants from the NCI, multiple publications and brisk accrual to translational clinical trials.
The University of Iowa/Mayo Clinic Lymphoma SPORE is funded by the NCI, which awarded Mayo Clinic a five-year grant in July 2012 for $11.7 million. A SPORE, or Specialized Program of Research Excellence, is a cornerstone of the NCI's efforts to promote collaborative, interdisciplinary translational cancer research.
The principal investigators for the University of Iowa/Mayo Clinic Lymphoma SPORE are: